Watchlists Idées ProPicks IA Screener Explorateur données Graphiques Travail sauvegardé

Intellia Therapeutics Inc

NASDAQGM:NTLA

États-Unis / Santé / Biotechnologie

Aperçu

Historique des finances 10 ans

Prix Action

8,70 USD


Key Metrics	Latest
Total Revenue	57,877 M
Adjusted EBITDA	-524 M
EBITDA Margin	-905,3%
Net Profit Margin	-855,1%
Total Assets	1,191 B
Total Debt	210,2 M

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	6	16	26	30	43	58	33	52	36	58	58
% Growth		172.7%	58.5%	16.5%	41.6%	34.5%	-43.0%	57.7%	-30.4%	59.6%

Adjusted EBITDA	(13)	(31)	(67)	(86)	(101)	(130)	(261)	(451)	(506)	(524)	(524)
% Margin	-216.4%	-188.5%	-254.9%	-283.9%	-233.8%	-224.6%	-789.5%	-864.5%	-1395.8%	-905.3%	-905.3%

Adjusted EBIT	(13)	(32)	(70)	(91)	(106)	(137)	(268)	(458)	(515)	(534)	(534)
% Margin	-221.9%	-195.2%	-266.3%	-298.6%	-246.8%	-235.5%	-810.4%	-879.0%	-1420.5%	-923.1%	-923.1%

Adjusted Net Income	(12)	(32)	(68)	(85)	(100)	(134)	(268)	(464)	(481)	(495)	(495)
% Margin	-205.1%	-192.0%	-258.6%	-280.4%	-230.9%	-231.5%	-810.5%	-890.6%	-1326.3%	-855.1%	-855.1%

Adjusted Basic EPS	(51.02)	(1.42)	(1.88)	(1.98)	(2.11)	(2.40)	(3.78)	(6.03)	(5.42)	(5.01)	(5.01)

Calculs d'appui

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
USD	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	6	16	26	30	43	58	33	52	36	58	58
% Growth	NA	172.7%	58.5%	16.5%	41.6%	34.5%	-43.0%	57.7%	-30.4%	59.6%

Cost of Revenue	(11)	(32)	(68)	(89)	(108)	(150)	(230)	(420)	(435)	(466)	(466)
Gross Profit	(5)	(15)	(42)	(59)	(65)	(92)	(197)	(368)	(399)	(408)	(408)
% Revenue	-84.8%	-93.2%	-159.0%	-192.8%	-151.5%	-159.4%	-595.3%	-705.8%	-1099.4%	-705.7%	-705.7%

Research and Development	(11)	(32)	(68)	(89)	(108)	(150)	(230)	(420)	(435)	(466)	(466)
Selling and Marketing	0	0	0	0	0	0	0	0	0	0	0
General and Admin	(8)	(17)	(28)	(32)	(41)	(44)	(71)	(90)	(116)	(126)	(126)
Other Inc / (Exp)	11	32	68	89	108	150	228	395	419	434	434
Total Operating Exp	(8)	(17)	(28)	(32)	(41)	(44)	(72)	(115)	(132)	(158)	(158)

Operating Income	(13)	(32)	(70)	(91)	(106)	(137)	(269)	(483)	(531)	(567)	(567)
% Revenue	-221.9%	-195.2%	-266.3%	-298.6%	-246.8%	-235.5%	-814.4%	-926.2%	-1463.9%	-979.4%	-979.4%

Interest Expense	0	1	2	6	7	2	1	9	50	48	48
Pre-tax Income	(13)	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(519)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	1	0	0	0	0	0	0	0	0	0	0
Net Income to Company	(12)	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(519)
% Margin	-205.1%	-192.0%	-258.6%	-280.4%	-230.9%	-231.5%	-810.5%	-909.8%	-1326.5%	-896.8%	-896.8%

Minority Interest in Earnings	0	0	0	0	0	0	0	0	0	0	0
Net Income to Stockholders	(12)	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(519)

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	(12)	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(519)
% Margin	-205.1%	-192.0%	-258.6%	-280.4%	-230.9%	-231.5%	-810.5%	-909.8%	-1326.5%	-896.8%	-896.8%

As Reported
Basic EPS (Continuing Ops)	(51.02)	(1.42)	(1.88)	(1.98)	(2.11)	(2.40)	(3.78)	(6.16)	(5.42)	(5.25)	(5.25)
Diluted EPS (Continuing Ops)	(51.02)	(1.42)	(1.88)	(1.98)	(2.11)	(2.40)	(3.78)	(6.16)	(5.42)	(5.25)	(5.25)

WA Basic Shares Out.	0.24	22.22	36.01	43.07	47.25	55.99	70.89	76.97	88.77	98.85	98.85
WA Diluted Shares Out.	0.24	22.22	36.01	43.07	47.25	55.99	70.89	76.97	88.77	98.85	98.85

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(13)	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(519)
Addback: Net Interest Expense	0	(1)	(2)	(6)	(7)	(2)	(1)	(9)	(50)	(48)	(48)
Addback: Other Non Operating Expenses, Total	0	0	0	0	0	0	1	11	16	0	0
Addback: Depreciation & Amortization	0	1	3	4	6	6	7	8	9	10	10
Addback: Restructuring Charges	0	0	0	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0	0	33	33
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	13	0	0	0
Adjusted EBITDA	(13)	(31)	(67)	(86)	(101)	(130)	(261)	(451)	(506)	(524)	(524)
% Margin	-216.4%	-188.5%	-254.9%	-283.9%	-233.8%	-224.6%	-789.5%	-864.5%	-1395.8%	-905.3%	-905.3%

Adjusted EBIT	(13)	(32)	(70)	(91)	(106)	(137)	(268)	(458)	(515)	(534)	(534)
% Margin	-221.9%	-195.2%	-266.3%	-298.6%	-246.8%	-235.5%	-810.4%	-879.0%	-1420.5%	-923.1%	-923.1%

Adjusted Net Income Reconciliation
Net Income to Company	(12)	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(519)
Addback: Unusual Items	0	0	0	0	0	0	0	13	0	33	33
Less: Tax Benefit of Unusual Items (26%)	0	0	0	0	0	0	0	(4)	(0)	(8)	(8)
Adjusted Net Income	(12)	(32)	(68)	(85)	(100)	(134)	(268)	(464)	(481)	(495)	(495)
% Margin	-205.1%	-192.0%	-258.6%	-280.4%	-230.9%	-231.5%	-810.5%	-890.6%	-1326.3%	-855.1%	-855.1%

Erreur de Chargement

Intellia Therapeutics Inc

NASDAQGM:NTLA

États-Unis / Santé / Biotechnologie

Historique des finances 10 ans